Quarter
Charts🇺🇸US Markets

MIRA Pharmaceuticals, Inc.

MIRA

CIK 0001904286 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$53K
↑+39.5% +$15Kvs FY2024 (Q4)
Gross Profit
$53K
↑+39.5% +$15Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0Insufficient data
  • Liquidity
    100Current Ratio 15.75 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.01x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +39.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Stock-based comp (TTM)
$6M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$11M
everything owned
Total liabilities
$702K
everything owed
Stockholders' equity
$10M
shareholder claim

Recent performance · 16 quarters

Revenue↑+39.5% +$15K
$53K
Net Income↑+44.3% +$906K
$-1M
Free Cash Flow↓-55.3% -$580K
$-2M

Drill down

MIRA Sankey

See MIRA Pharmaceuticals, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

MIRA Charts

16 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

MIRA Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics